10:28 AM EST - Bausch Health Companies Inc. : Said its Bausch + Lomb division announced statistically significant topline data from the second Phase 3 (MOJAVE) trial evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). The companies announced statistically significant topline data from the first Phase 3 trial (GOBI trial) in April 2021. Bausch Health Companies Inc.
shares T.BHC are trading down $0.45 at $35.42.
